{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:47:19Z","timestamp":1787316439230,"version":"build-2736575974"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SPP1656"],"award-info":[{"award-number":["SPP1656"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR241"],"award-info":[{"award-number":["TRR241"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["C04"],"award-info":[{"award-number":["C04"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bpg.2021.101763","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T05:44:07Z","timestamp":1638855847000},"page":"101763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["New agents for immunosuppression"],"prefix":"10.1016","volume":"54-55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2041-269X","authenticated-orcid":false,"given":"Andr\u00e9","family":"Jefremow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus F.","family":"Neurath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.bpg.2021.101763_bib2","article-title":"Diagnostic criteria for systemic lupus erythematosus: a critical review","volume":"48\u201349","author":"Yu","year":"2014","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000500721","article-title":"Mechanism-Based treatment strategies for IBD: cytokines, cell adhesion molecules, JAK inhibitors","volume":"4","author":"Schreiner","year":"2019","journal-title":"Gut Flora, and More. Inflamm Intest Dis"},{"key":"10.1016\/j.bpg.2021.101763_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/ITT.S282466","article-title":"All are equal, some are more equal: targeting IL 12 and 23 in IBD \u2013 a clinical perspective","volume":"9","author":"Jefremow","year":"2020","journal-title":"ImmunoTargets Ther"},{"issue":"18","key":"10.1016\/j.bpg.2021.101763_bib5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N Engl J Med"},{"issue":"10080","key":"10.1016\/j.bpg.2021.101763_bib6","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib7","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1053\/j.gastro.2010.01.058","article-title":"Inflammation and colon cancer","volume":"138","author":"Terzi\u0107","year":"2010","journal-title":"Gastroenterology [Internet]"},{"issue":"May","key":"10.1016\/j.bpg.2021.101763_bib8","first-page":"1","article-title":"Targeting immune cell trafficking \u2013 insights from research models and implications for future IBD therapy","volume":"12","author":"Wiendl","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib9","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","volume":"182","author":"Neurath","year":"1995","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.bpg.2021.101763_bib10","first-page":"870","article-title":"Investigation of the relationship between the Th17\/IL-23 pathway and innate-adaptive immune system in TNBS-induced colitis in rats","volume":"20","author":"Karaboga","year":"2017","journal-title":"Iran J Basic Med Sci"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib11","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib12","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.4049\/jimmunol.177.5.2760","article-title":"Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis","volume":"177","author":"Becker","year":"2006","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.bpg.2021.101763_bib13","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1084\/jem.20061082","article-title":"IL-23 plays a key role in Helicobacter hepaticus\u2013induced T cell\u2013dependent colitis","volume":"203","author":"Kullberg","year":"2006","journal-title":"J Exp Med"},{"issue":"5804","key":"10.1016\/j.bpg.2021.101763_bib14","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science (80- )"},{"issue":"11","key":"10.1016\/j.bpg.2021.101763_bib15","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/gut.2011.238477","article-title":"Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease","volume":"60","author":"Kim","year":"2011","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/ibd\/izy085","article-title":"Determinants of IBD heritability: genes, bugs, and more","volume":"24","author":"Turpin","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/MCG.0b013e318168bdf0","article-title":"Genetic variants in IL-23R and ATG16L1 independently predispose to increased susceptibility to Crohn's disease in a Canadian population","volume":"43","author":"Newman","year":"2009","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ibd.20126","article-title":"IL-23 receptor (IL-23R) gene protects against pediatric Crohn\u02bcs disease","volume":"13","author":"Dubinsky","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10067-013-2469-y","article-title":"Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results","volume":"33","author":"Gheita","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/nm0107-26","article-title":"IL-23: a master regulator in Crohn disease","volume":"13","author":"Neurath","year":"2007","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajg.2018.09.003","article-title":"Evaluation of interleukin 23 (IL-23) as a non-invasive test of disease severity in patients with ulcerative colitis","volume":"19","author":"Youssef","year":"2018","journal-title":"Arab J Gastroenterol"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1189\/jlb.0810456","article-title":"The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity","volume":"89","author":"Liu","year":"2011","journal-title":"J Leukoc Biol"},{"issue":"10","key":"10.1016\/j.bpg.2021.101763_bib23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","article-title":"Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study","volume":"3","author":"Feagan","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.bpg.2021.101763_bib24","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/ecco-jcc\/jjy099","article-title":"Selective IL-23 inhibition by Risankizumab modulates the molecular profile in the colon and ileum of patients with active Crohn's disease: results from a randomised phase II biopsy sub-study","volume":"12","author":"Visvanathan","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.bpg.2021.101763_bib25","article-title":"IL12\/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?","volume":"38\u201339","author":"Ma","year":"2019","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/13543784.2019.1597053","article-title":"Expert opinion on interleukin-12\/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease","volume":"28","author":"Wong","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","article-title":"Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: a phase 2a study","volume":"153","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(18)34449-4","article-title":"882 - efficacy and safety of anti-interleukin-23 therapy with mirikizumab (LY3074828) in patients with moderate-to-severe ulcerative colitis in a phase 2 study","volume":"154","author":"Sandborn","year":"2018","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.bpg.2021.101763_bib29","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1365-2036.2006.02910.x","article-title":"A Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis","volume":"23","author":"Van Deventer","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.bpg.2021.101763_bib30","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1365-2036.2006.02837.x","article-title":"Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial","volume":"23","author":"Miner","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2036.2004.01863.x","article-title":"An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis","volume":"19","author":"Miner","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.bpg.2021.101763_bib32","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1136\/gut.2003.036160","article-title":"A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis","volume":"53","author":"van Deventer","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2021.101763_bib33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(17)30930-3","article-title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"390","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bpg.2021.101763_bib34","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1136\/gutjnl-2016-313457","article-title":"Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study","volume":"67","author":"Sandborn","year":"2018","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5217\/ir.2019.00039","article-title":"Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study","volume":"18","author":"Saruta","year":"2020","journal-title":"Int Res"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/ecco-jcc\/jjx121","article-title":"Anti-MAdCAM antibody increases \u00df7+ T cells and CCR9 gene expression in the peripheral blood of patients with Crohn's disease","volume":"12","author":"Hassan-Zahraee","year":"2018","journal-title":"J Crohn\u2019s Colitis"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib37","doi-asserted-by":"crossref","first-page":"738","DOI":"10.14309\/ajg.0000000000000493","article-title":"Mongersen (GED-0301) for active Crohn's disease: results of a phase 3 study","volume":"115","author":"Sands","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.bpg.2021.101763_bib38","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","article-title":"Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease","volume":"372","author":"Monteleone","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2021.101763_bib39","first-page":"1","article-title":"Targeting of the Tec kinase ITK drives resolution of T cell-mediated colitis and emerges as potential therapeutic option in ulcerative colitis","author":"Lechner","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib40","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","article-title":"A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease\u2606","volume":"126","author":"Ito","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/gutjnl-2017-314562","article-title":"Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.bpg.2021.101763_bib42","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s10067-011-1827-x","article-title":"Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review","volume":"30","author":"Gout","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.bpg.2021.101763_bib43","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/j.cgh.2019.12.032","article-title":"Effects of apremilast, an oral inhibitor of Phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis","volume":"18","author":"Danese","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.bpg.2021.101763_bib44","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.bpg.2021.101763_bib45","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"10066","key":"10.1016\/j.bpg.2021.101763_bib46","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.bpg.2021.101763_bib47","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bpg.2021.101763_bib48","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.20732","article-title":"Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome","volume":"42","author":"Feld","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2021.101763_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919861914","article-title":"The risk of liver cancer in autoimmune liver diseases","author":"Lleo","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","article-title":"Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission","volume":"58","author":"van Gerven","year":"2013","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S2468-1253(20)30328-9","article-title":"Established and novel therapeutic options for autoimmune hepatitis","volume":"6","author":"Liberal","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2021.101763_bib53","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2014.04.022","article-title":"Genome-wide association study identifies variants associated with autoimmune hepatitis type 1","volume":"147","author":"De Boer","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.autrev.2010.09.024","article-title":"Autoimmune hepatitis, HLA and extended haplotypes","volume":"10","author":"Oliveira","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib55","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"issue":"33","key":"10.1016\/j.bpg.2021.101763_bib56","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.3748\/wjg.v23.i33.6030","article-title":"Autoimmune hepatitis: standard treatment and systematic review of alternative treatments","volume":"23","author":"Beretta-Piccoli","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib57","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0016-5085(94)90426-X","article-title":"Primary and secondary liver\/kidney microsomal autoantibody response following infection with hepatitis C virus","volume":"106","author":"Mackie","year":"1994","journal-title":"Gastroenterology"},{"issue":"1\u20134","key":"10.1016\/j.bpg.2021.101763_bib58","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000150301","article-title":"Viruses and autoimmune liver disease","volume":"35","author":"Manns","year":"1993","journal-title":"Intervirology"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib59","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bj\u00f6rnsson","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib60","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bpg.2011.09.009","article-title":"Pathogenesis of autoimmune hepatitis","volume":"25","author":"Liberal","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.bpg.2021.101763_bib61","volume":"vol. 6","author":"Zhao","year":"2011"},{"issue":"2","key":"10.1016\/j.bpg.2021.101763_bib62","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2249.2009.03947.x","article-title":"Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis","volume":"157","author":"Harada","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM197807062990101","article-title":"Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis","volume":"299","author":"Jensen","year":"1978","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bpg.2021.101763_bib64","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/0891693021000056721","article-title":"Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease","volume":"35","author":"Gregorio","year":"2002","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.bpg.2021.101763_bib65","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.26666","article-title":"Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis","volume":"59","author":"Couto","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib66","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.27991","article-title":"Depletion of B cells induces remission of autoimmune hepatitis in mice through reduced antigen presentation and help to T cells","volume":"62","author":"B\u00e9land","year":"2015","journal-title":"Hepatology"},{"issue":"JUN","key":"10.1016\/j.bpg.2021.101763_bib67","first-page":"1","article-title":"Multiple treg suppressive modules and their adaptability","volume":"3","author":"Wing","year":"2012","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib68","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib69","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hep.27884","article-title":"In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression","volume":"62","author":"Liberal","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib70","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2005.05.001","article-title":"Effect of CD4+CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis","volume":"25","author":"Longhi","year":"2005","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib71","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.510250308","article-title":"Autoimmune hepatitis in childhood: a 20-year experience","volume":"25","author":"Gregorio","year":"1997","journal-title":"Hepatology"},{"issue":"7216","key":"10.1016\/j.bpg.2021.101763_bib72","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nature07336","article-title":"Innate immunity and intestinal microbiota in the development of Type 1 diabetes","volume":"455","author":"Wen","year":"2008","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib73","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/hep.27998","article-title":"A novel \u201chumanized mouse\u201d model for autoimmune hepatitis and the association of gut microbiota with liver inflammation","volume":"62","author":"Yuksel","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib74","first-page":"5153","article-title":"Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis","volume":"8","author":"Lin","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib75","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/liv.14062","article-title":"Autoimmune hepatitis: current and future therapeutic options","volume":"39","author":"Doycheva","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.bpg.2021.101763_bib76","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells","volume":"173","author":"Ng","year":"2004","journal-title":"J Immunol"},{"issue":"February","key":"10.1016\/j.bpg.2021.101763_bib77","article-title":"JKB-122 is effective, alone or in combination with prednisolone in Con A-induced hepatitis","volume":"812","author":"Hsu","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/j.bpg.2021.101763_bib78","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.humimm.2007.03.010","article-title":"Elevated serum BAFF levels in patients with autoimmune hepatitis","volume":"68","author":"Migita","year":"2007","journal-title":"Hum Immunol"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib79","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.28517","article-title":"Human intrahepatic regulatory T cells are functional, require IL\u20102 from effector cells for survival, and are susceptible to Fas ligand\u2010mediated apoptosis","volume":"64","author":"Chen","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib80","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1053\/j.gastro.2008.06.042","article-title":"Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling","volume":"135","author":"Kido","year":"2008","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib81","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/hep.26583","article-title":"Dysfunctional CD39 POS regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis","volume":"59","author":"Grant","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib82","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep4.1163","article-title":"Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis","volume":"2","author":"Jeffery","year":"2018","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.bpg.2021.101763_bib83","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/hep.25682","article-title":"The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9\/tim-3 pathway","volume":"56","author":"Liberal","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bpg.2021.101763_bib84","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2009.08.007","article-title":"Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis","volume":"9","author":"D\u00f6rner","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib85","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/106689690301100414","article-title":"Testicular ischemia due to intravascular large B-cell lymphoma: a novel presentation in an immunosuppressed individual","volume":"11","author":"Tranchida","year":"2003","journal-title":"Int J Surg Pathol"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib86","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1159\/000322693","article-title":"A case of autoimmune hepatitis treated with rituximab","volume":"4","author":"Barth","year":"2010","journal-title":"Case Rep Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib87","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2013\/512624","article-title":"Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy","volume":"27","author":"Burak","year":"2013","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib88","first-page":"141","article-title":"Cholestatic liver disease: current treatment strategies and new therapeutic agents","volume":"58","author":"Hasegawa","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib89","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib90","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2021.101763_bib91","first-page":"1161","article-title":"Primary sclerosing cholangitis","volume":"vol. 375","author":"Lazaridis","year":"2016"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib92","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.bpg.2021.101763_bib93","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","article-title":"Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD","volume":"65","author":"Sabino","year":"2016","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib94","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.1840100406","article-title":"Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis","volume":"10","author":"Wiesner","year":"1989","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib95","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/hep.26447","article-title":"Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis","volume":"58","author":"Katt","year":"2013","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bpg.2021.101763_bib96","doi-asserted-by":"crossref","first-page":"926","DOI":"10.4254\/wjh.v7.i7.926","article-title":"Primary biliary cirrhosis: pathophysiology, clinical presentation and therapy","volume":"7","author":"Purohit","year":"2015","journal-title":"World J Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib97","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib98","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.det.2018.02.008","article-title":"Management of chronic hepatic itch","volume":"36","author":"D\u00fcll","year":"2018","journal-title":"Dermatol Clin"},{"issue":"9","key":"10.1016\/j.bpg.2021.101763_bib99","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11894-019-0713-6","article-title":"Treatment of pruritus secondary to liver disease","volume":"21","author":"D\u00fcll","year":"2019","journal-title":"Curr Gastroenterol Rep"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib100","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.25748","article-title":"Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions","volume":"56","author":"Kremer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2021.101763_bib101","article-title":"Lysophosphatidic acid activates nociceptors and causes pain or itch depending on the application mode in human skin","author":"D\u00fcll","year":"2021","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib103","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib105","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpgasthep0521","article-title":"Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis","volume":"3","author":"Beuers","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib106","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/hep.25992","article-title":"\u03b1 5 \u03b2 1 -integrins are sensors for tauroursodeoxycholic acid in hepatocytes","volume":"57","author":"Gohlke","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib107","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2012.02.014","article-title":"Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health","volume":"57","author":"Dilger","year":"2012","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib108","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","article-title":"Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial","volume":"30","author":"Angulo","year":"1999","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib109","doi-asserted-by":"crossref","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.bpg.2021.101763_bib110","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases","volume":"7","author":"Thomas","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.bpg.2021.101763_bib111","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2036.2011.04822.x","article-title":"Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis","volume":"34","author":"Triantos","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.bpg.2021.101763_bib112","doi-asserted-by":"crossref","DOI":"10.1111\/liv.13110","article-title":"Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value","volume":"36","author":"de Vries","year":"2016","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.bpg.2021.101763_bib113","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cgh.2011.03.019","article-title":"Prevalence of primary biliary cirrhosis\u2013autoimmune hepatitis overlap syndrome","volume":"9","author":"Bonder","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2021.101763_bib114","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2008.03722.x","article-title":"Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival","volume":"28","author":"AL-Chalabi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib115","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cgh.2013.09.021","article-title":"Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis","volume":"12","author":"Ozaslan","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2021.101763_bib116","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hepr.12210","article-title":"Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: importance of corticosteroid therapy","volume":"44","author":"Yoshioka","year":"2014","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.bpg.2021.101763_bib117","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouill\u00e8res","year":"1998","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib118","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3390\/jcm9051449","article-title":"Treatment of overlap syndromes in autoimmune liver disease: a systematic review and meta-analysis","volume":"9","author":"Freedman","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib119","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MCG.0b013e318157c614","article-title":"Characteristics and long-term prognosis of the autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"43","author":"L\u00fcth","year":"2009","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"10.1016\/j.bpg.2021.101763_bib120","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1572-0241.2005.41841.x","article-title":"Clinical course and outcome of autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"100","author":"Floreani","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2021.101763_bib121","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib122","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrgastro.2015.12","article-title":"Novel therapeutic targets in primary biliary cirrhosis","volume":"12","author":"Dyson","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.bpg.2021.101763_bib123","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.bbadis.2010.12.018","article-title":"Molecular basis for gene-specific transactivation by nuclear receptors","volume":"1812","author":"Aagaard","year":"2011","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"issue":"15","key":"10.1016\/j.bpg.2021.101763_bib124","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.1073\/pnas.91.15.7355","article-title":"Differential expression and activation of a family of murine peroxisome proliferator-activated receptors","volume":"91","author":"Kliewer","year":"1994","journal-title":"Proc Natl Acad Sci Unit States Am"},{"issue":"23","key":"10.1016\/j.bpg.2021.101763_bib125","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib126","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"Open Cardiovasc Med J"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib127","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1751-2980.2012.00574.x","article-title":"Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy","volume":"13","author":"Han","year":"2012","journal-title":"J Dig Dis"},{"issue":"10","key":"10.1016\/j.bpg.2021.101763_bib128","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib129","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib130","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2021.101763_bib131","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"scp>NGM<\/scp> 282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double\u2010blind, placebo\u2010controlled trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.bpg.2021.101763_bib132","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib133","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib134","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"issue":"February","key":"10.1016\/j.bpg.2021.101763_bib135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2019.04.005","article-title":"Therapeutic trials of biologics in primary biliary cholangitis: an open label study of abatacept and review of the literature","volume":"101","author":"Bowlus","year":"2019","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib136","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib137","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib138","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2016-312049","article-title":"Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis","volume":"66","author":"Masamune","year":"2017","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.bpg.2021.101763_bib139","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1111\/j.1572-0241.2000.02323.x","article-title":"Oral budesonide in the treatment of primary sclerosing cholangitis","volume":"95","author":"Angulo","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2021.101763_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/0016-5085(94)90610-6","article-title":"A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis","volume":"106","author":"Knox","year":"1994","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.bpg.2021.101763_bib141","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/MEG.0b013e3282f5197e","article-title":"Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study","volume":"20","author":"Vleggaar","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib142","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat Microbiol"},{"issue":"2","key":"10.1016\/j.bpg.2021.101763_bib143","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.advms.2020.07.002","article-title":"Autoimmune pancreatitis \u2013 an ongoing challenge","volume":"65","author":"Blaho","year":"2020","journal-title":"Adv Med Sci"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib144","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1111\/jcmm.13537","article-title":"Adoptive transfer of <scp>CD<\/scp> 3 + T cells and <scp>CD<\/scp> 4 + <scp>CD<\/scp> 44 high memory T cells induces autoimmune pancreatitis in <scp>MRL<\/scp>\/MpJ mice","volume":"22","author":"Ehlers","year":"2018","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.bpg.2021.101763_bib145","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1055\/s-0034-1366687","article-title":"Ergebnisse einer S2k-Konsensuskonferenz der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselerkrankungen (DGVS) gemeinsam mit der Deutschen Z\u00f6liakie-Gesellschaft (DZG) zur Z\u00f6liakie, Weizenallergie und Weizensensitivit\u00e4t","volume":"52","author":"Felber","year":"2014","journal-title":"Z Gastroenterol"},{"issue":"10115","key":"10.1016\/j.bpg.2021.101763_bib146","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0140-6736(17)31796-8","article-title":"Coeliac disease","volume":"391","author":"Lebwohl","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bpg.2021.101763_bib147","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.dld.2019.11.010","article-title":"Therapeutic options for coeliac disease: what else beyond gluten-free diet?","volume":"52","author":"Caio","year":"2020","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib148","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2741\/1843","article-title":"Tissue transglutaminase (TG2) - a wound response enzyme","volume":"11","author":"Telci","year":"2006","journal-title":"Front Biosci"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib149","doi-asserted-by":"crossref","DOI":"10.1021\/ja056423o","article-title":"Inhibition of HLA-DQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from \u03b12-gliadin","volume":"128","author":"Xia","year":"2006","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2032441","article-title":"A randomized trial of a transglutaminase 2 inhibitor for celiac disease","volume":"385","author":"Schuppan","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2007.10.091","article-title":"Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses associated with Celiac disease","volume":"16","author":"Kapoerchan","year":"2008","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"10.1016\/j.bpg.2021.101763_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.molimm.2009.10.036","article-title":"Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule","volume":"47","author":"Kapoerchan","year":"2010","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1016\/j.bpg.2021.101763_bib153","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/gast.2000.18149","article-title":"Interleukin 15 mediates epithelial changes in celiac disease","volume":"119","author":"Maiuri","year":"2000","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.bpg.2021.101763_bib154","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2468-1253(19)30265-1","article-title":"Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study","volume":"4","author":"Cellier","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.bpg.2021.101763_bib155","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2468-1253(19)30264-X","article-title":"Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study","volume":"4","author":"L\u00e4hdeaho","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2021.101763_bib156","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.coi.2013.02.004","article-title":"Vaccine against autoimmune disease: antigen-specific immunotherapy","volume":"25","author":"Anderson","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.bpg.2021.101763_bib157","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ebiom.2017.11.018","article-title":"Epitope-specific immunotherapy targeting CD4-positive T cells in celiac disease: safety, pharmacokinetics, and effects on intestinal histology and plasma cytokines with escalating dose regimens of Nexvax2 in a randomized, double-blind, placebo-controlled","volume":"26","author":"Daveson","year":"2017","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.bpg.2021.101763_bib158","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.mayocp.2016.03.001","article-title":"A refractory celiac patient successfully treated with mesenchymal stem cell infusions","volume":"91","author":"Ciccocioppo","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bpg.2021.101763_bib159","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000506908","article-title":"Nanoparticles in gastrooncology","author":"Jefremow","year":"2020","journal-title":"Vis Med"},{"issue":"1","key":"10.1016\/j.bpg.2021.101763_bib160","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm0107-26","article-title":"IL-23: a master regulator in Crohn disease","volume":"13","author":"Neurath","year":"2007","journal-title":"Nat Med"}],"container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691821000433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691821000433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:04:04Z","timestamp":1778616244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691821000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":160,"alternative-id":["S1521691821000433"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2021.101763","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New agents for immunosuppression","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2021.101763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101763"}}